24/7 Market News Snapshot 17 March, 2025 – Pliant Therapeutics, Inc. Common Stock (NASDAQ:PLRX)

March 17, 2025

DENVER, Colo., 17 March, 2025 (247marketnews.com) – (NASDAQ:PLRX) are discussed in this article.
Pliant Therapeutics, Inc. (PLRX) has garnered notable attention in the market today, with its share price rising significantly by 11.69%, currently trading at $1.72 following an opening at $1.55. The company is witnessing robust investor interest, as evidenced by a heightened trading volume of 3.21 million shares. This sharp price increase reflects growing positive market sentiment, likely fueled by recent encouraging developments surrounding its clinical pipeline. Investors are advised to monitor critical resistance levels around $1.75, while support trends may solidify near the day’s opening price. Continued upward momentum could signal additional buying opportunities for both short-term traders and long-term stakeholders.

In parallel with its strong market performance, Pliant has announced promising interim results from its ongoing Phase 1 dose escalation clinical trial of PLN-101095, a novel dual integrin αvβ8 and αvβ1 inhibitor. The trial, which is assessing the safety and preliminary antitumor activity of PLN-101095 in combination with pembrolizumab for patients with advanced or metastatic solid tumors resistant to immune checkpoint inhibitors (ICIs), has reported a remarkable 50% objective response rate in its third cohort. Among six patients treated at the highest dose of 1000 mg twice daily, three achieved confirmed partial responses, with significant tumor reductions observed across various cancer types, including non-small cell lung cancer, cholangiocarcinoma, and melanoma.

Dr. Éric Lefebvre, Chief Medical Officer of Pliant, expressed optimism regarding the trial’s early results, highlighting the treatment’s potential in a notably challenging patient population. As the trial progresses into its fourth cohort, which evaluates an alternative dosing regimen, PLN-101095 emerges as a promising candidate in the landscape of oncology therapeutics, with the potential to offer new hope to patients facing limited treatment options. Further insights from this trial will be anticipated as they become available.

Related news for (PLRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.